GRCE vs REGN · $35.0M cap vs P/E 14, rev $14.34B
Grace Therapeutics, Inc. (GRCE) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
GRCE does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
GRCE currently screens at market cap $35.0M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the GRCE and REGN stock pages for the full models.
Not investment advice.